Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials

Erasca (ERAS) provided updated preliminary Phase 1 data for ERAS-0015, reporting encouraging early activity in RAS-mutant solid tumors and planning next steps toward potentially registration-enabling studies. The update is positive for clinical momentum, but remains early-stage with limited quantitative specifics in the report.

Analysis

Erasca (ERAS) provided updated preliminary Phase 1 data for ERAS-0015, reporting encouraging early activity in RAS-mutant solid tumors and planning next steps toward potentially registration-enabling studies. The update is positive for clinical momentum, but remains early-stage with limited quantitative specifics in the report.